Microtubule-associated protein tau (MAPT) iRNA preparation composition and method of use thereof
RNAi compositions targeting the MAPT gene inhibit expression by 25% to 95%, addressing the need for effective tauopathy treatments by reducing tau aggregates and improving therapeutic outcomes for Alzheimer's disease and related disorders.
JP2026116278APending Publication Date: 2026-07-09ALNYLAM PHARMACEUTICALS INC
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- ALNYLAM PHARMACEUTICALS INC
- Filing Date
- 2026-03-02
- Publication Date
- 2026-07-09
Smart Images
Figure 2026116278000001_ABST
Abstract
This invention provides a double-stranded ribonucleic acid interference (dsRNAi) agent that targets the microtubule-associated protein tau (MAPT) gene. [Solution] A double-stranded ribonucleic acid (dsRNA) agent for inhibiting MAPT expression is provided, wherein the dsRNA agent comprises a sense strand and an antisense strand that form a double-stranded region, and the sense strand and antisense strand each contain a nucleotide sequence having a specific sequence and at least 15 consecutive nucleotides that differ by 3 or fewer nucleotides.
Need to check novelty before this filing date? Find Prior Art